Effectiveness, Safety, and Health-Related Quality of Life in Moderate-to-Severe Atopic Dermatitis Treated with Lebrikizumab: A 16-Week Nationwide Retrospective Cohort Study

Abstract Introduction Atopic dermatitis (AD) is a chronic inflammatory skin condition that significantly affects the quality of life (QoL). Lebrikizumab, a biologic drug targeting interleukin-13, demonstrated efficacy and safety in clinical trials. However, real-world data remain limited, largely re...

সম্পূর্ণ বিবরণ

গ্রন্থ-পঞ্জীর বিবরন

প্রধান লেখক:	Gianluca Avallone, Andrea Bombelli, Luigi Gargiulo, Caterina Foti, Ilaria Trave, Mariateresa Rossi, Elisabetta Magnaterra, Flavia Pigliacelli, Piergiorgio Malagoli, Serena Giacalone, Antonio Portarapillo, Cataldo Patruno, Natale Schettini, Laura Bonzano, Elena Pezzolo, Camilla Chello, Niccolò Gori, Giovanna Brunasso, Federica Veronese, Michela Ortoncelli, Ersilia Tolino, Alan Azzolini, Francesco Bellinato, Katharina Hansel, Eugenia Veronica Di Brizzi, Carlotta Gurioli, Maria Esposito, Roberta Giuffrida, Francesca Barei, Paolo Calzari, Anna Graziella Burroni, Massimo Gola, Maria Mariano, Maria Concetta Fargnoli, Maddalena Napolitano, Teresa Grieco, Ketty Peris, Paola Savoia, Simone Ribero, Giampiero Girolomoni, Luca Stingeni, Anna Balato, Antonio Costanzo, Angelo Valerio Marzano, Alessandra Narcisi, Silvia Mariel Ferrucci
বিন্যাস:	Artigo
ভাষা:	Inglês
প্রকাশিত:	Adis, Springer Healthcare 2025-10-01
মালা:	Dermatology and Therapy
বিষয়গুলি:	Biologics Monoclonal antibodies IL-13 inhibitor Skin disease Atopic dermatitis Lebrikizumab
অনলাইন ব্যবহার করুন:	https://doi.org/10.1007/s13555-025-01550-8
ট্যাগগুলো:	ট্যাগ যুক্ত করুন কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!